Hayward (HAYW) CFO Executes 10b5-1 Plan: Option Exercise and Share Sale
Rhea-AI Filing Summary
Jones Eifion, Senior Vice President and Chief Financial Officer of Hayward Holdings, Inc. (HAYW), reported paired transactions dated 08/13/2025. Under a Rule 10b5-1 plan (box checked), Mr. Eifion exercised 20,000 stock options with an exercise price of $1.40, acquiring 20,000 shares, and simultaneously sold 20,000 common shares at $16.50 per share. After these transactions, the filing shows 287,231 shares of common stock beneficially owned directly and 915,375 shares underlying derivative securities owned directly. The option had vested on April 20, 2025. The Form 4 was signed by an attorney-in-fact on 08/14/2025.
Positive
- Transaction executed under a Rule 10b5-1 plan, indicating preplanned trading activity
- Options had vested prior to exercise (vested on 04/20/2025), so exercise was not contingent on new vesting
- Substantial remaining derivative holdings reported (915,375 underlying shares), showing continued insider exposure
Negative
- Sale of 20,000 shares reduced direct holdings from 307,231 to 287,231 shares
- Timing and pricing show immediate monetization at $16.50 per share, which may be viewed as partial liquidity realization
Insights
TL;DR Insider exercised vested options and sold an equal number of shares under a 10b5-1 plan, leaving substantial derivative and direct holdings.
Mr. Eifion exercised 20,000 options at $1.40 and sold 20,000 shares at $16.50 on 08/13/2025. The filing explicitly notes the options vested on 04/20/2025 and that the transaction was processed pursuant to a Rule 10b5-1 plan. After the activity, direct beneficial ownership is reported at 287,231 shares and derivative holdings correspond to 915,375 underlying shares. For investors, this is a routine insider liquidity event using an established trading plan rather than ad hoc trading.
TL;DR The disclosure indicates orderly, preplanned insider activity with full vesting and attorney-in-fact execution, consistent with governance best practices.
The form shows the reporting officer used a documented process: the option vested earlier in April 2025 and the box for Rule 10b5-1 transactions is checked, which supports an affirmative defense to insider trading claims. The Form 4 was executed by an attorney-in-fact on 08/14/2025, indicating delegated signing. These details point to procedural compliance in insider reporting and transaction execution.